A Randomized, Open-Label, Comparative 3-way Treatment Crossover Study of 24-hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-using patients

Study identifier:D9612L00063

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Medical condition

Heartburn

Phase

Phase 4

Healthy volunteers

Study drug

Esomeprazole, Lansoprazole, Pantoprazole

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 01 Jun 2004

Primary Completion Date: 01 Nov 2004

Study Completion Date: 01 Nov 2004

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Oral	Drug: Esomeprazole 40mg Oral Other Name: Nexium
Experimental: 2 Oral	Drug: Lansoprazole 30mg Oral Other Name: Prevacid
Experimental: 3 Oral	Drug: Pantoprazole 40mg Oral Other Name: Protonix

"There is no result for the study"

Documents available

CSR-D9612L00063.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Paula Fernstrom

Nexium Global Product Director, AstraZeneca